Ustekinumab resistance in individuals with ulcerative colitis is associated with an alteration of a subset of proinflammatory mucosal regulatory T cells
Inflammatory Bowel Diseases · 01.06.2026 · 32 (6) · 1138-1152
DOI: 10.1093/ibd/izag059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 15.04.2026. Verfasst von Kristi C Briggs und 14 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United Stat…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Ustekinumab, T-Lymphocytes, Regulatory, Intestinal Mucosa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bloomberg Philanthropies, Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases within the National Institutes of Health (NIH), NIH.
Abstract (Originalsprache)
Background
Ustekinumab is a monoclonal antibody therapy targeting interleukin-12 and interleukin-23 for the treatment of inflammatory bowel diseases, including ulcerative colitis (UC). While these pathways remain quite attractive for UC therapy, response to ustekinumab can be variable. There is an urgent need to better understand the underlying mucosal immune alterations associated with treatment to guide therapy decisions. This study aims to examine the mucosal immune signatures in individuals with UC with variable treatment response to ustekinumab.
Methods
Sigmoid colon tissue from individuals treated with ustekinumab were analyzed using a multimodal approach. Single-cell RNA and T cell receptor sequencing was performed on mucosal biopsies. In a subset of these patients, multiparameter flow cytometry and spatial transcriptomics was also completed on matched pre- and post-treatment tissue samples. Key findings were also validated on a larger cohort using immunohistochemistry.
Results
Ustekinumab significantly altered the frequency and phenotype of mucosal regulatory T cells (Tregs). Nonresponders to ustekinumab had a higher frequency of Tregs that expressed OX40 and GITR, which is associated with decreased suppressive abilities. In contrast, responders had Tregs with elevated GPR15 and reduced expression of the kinase PIM2, which can alter Treg stability and function. Additionally, T helper 17 cells in nonresponders demonstrated an enhanced proinflammatory gene expression profile.
Conclusion
Nonresponse to ustekinumab in UC is linked to a mucosal immune environment enriched with proinflammatory T cell phenotypes and impaired regulatory T cell function. These findings suggest that Tregs are both targets and potential biomarkers of ustekinumab response, with their phenotypic and transcriptional features providing insight into mechanisms of therapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States.
- Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Department of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Division of Gastroenterology, Hackensack University Medical Center, Hackensack, NJ, United States.
- Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, United States.
ORCID-Profile: Kristi C Briggs, Cynthia L Sears
Förderung
- Bloomberg Philanthropies
- Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases within the National Institutes of Health (NIH)
- NIH
- U.S. government
- U.S. Department of Health and Human Services
- The Bloomberg Kimmel Institute for Cancer Immunotherapy
- NIH HHS
- National Institutes of Health
Zitieren
APA
Briggs, K. C., Tam, A., Chaaban, L., Luo, A., Kobeissi, L., Lazarev, M., Parian, A., Chowdhury, R., Selaru, F. M., Casella, K., Shenderov, E., Sears, C. L., Housseau, F., Melia, J. M. P., & Pardoll, D. M. (2026). Ustekinumab resistance in individuals with ulcerative colitis is associated with an alteration of a subset of proinflammatory mucosal regulatory T cells. Inflammatory Bowel Diseases, 32(6), 1138-1152. https://doi.org/10.1093/ibd/izag059
Vancouver
Briggs KC, Tam A, Chaaban L, Luo A, Kobeissi L, Lazarev M, et al. Ustekinumab resistance in individuals with ulcerative colitis is associated with an alteration of a subset of proinflammatory mucosal regulatory T cells. Inflammatory Bowel Diseases. 2026;32(6):1138-1152. doi:10.1093/ibd/izag059
BibTeX
@article{Briggs2026,
author = {Briggs, Kristi C and Tam, Ada and Chaaban, Lara and Luo, Adam and Kobeissi, Lynn and Lazarev, Mark and Parian, Alyssa and Chowdhury, Reezwana and Selaru, Florin M and Casella, Kelly and Shenderov, Eugene and Sears, Cynthia L and Housseau, Franck and Melia, Joanna M P and Pardoll, Drew M},
title = {Ustekinumab resistance in individuals with ulcerative colitis is associated with an alteration of a subset of proinflammatory mucosal regulatory T cells},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {6},
pages = {1138--1152},
doi = {10.1093/ibd/izag059}
}
EUVIMED